IRIDEX Corporation (IRIX) Earnings Call Transcripts

IRIDEX Corporation's Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, IRIDEX Corporation reported revenues of $11.8 million, essentially flat year-over-year, and a net loss of $0.5 million, an improvement from a loss of $1.7 million in the same period last year. Management reaffirmed full-year revenue guidance of $51 million to $53 million, indicating a pro forma growth of 1% to 5% compared to 2025. Key drivers included strong performance in the glaucoma segment, although international headwinds impacted retina sales, particularly in Asia and the Middle East.

Reported metrics

Guidance from management

Management reaffirmed full-year revenue guidance of $51 million to $53 million, excluding revenue from the Middle East, indicating a pro forma growth of 1% to 5% compared to 2025.

What management said

That backlog was around $800,000, and it was all retina. And we didn't -- we anticipated the EndoProbe backlog. We did not anticipate the regulatory. We'd hope to get that over the finish line. But as you know, with regulatory items, some of those things are up to the bodies of those countries. But going forward, we look for that revenue to ship this quarter. And -- yes.

Scott, this is Romeo. Thanks for the question. Yes. Basically, going forward now, we've -- over the last couple of quarters, we've been studying the reserves for the contract manufacturing transition of products. So we figured those part costs. We'd expect them there. That's why the margins were lower. But given even with the continued increase in our production costs, I think they've normalized in the high 30s, low ...

What analysts pressed on

Analysts expressed concerns regarding the lower-than-expected performance in the retina segment and the impact of international headwinds. There were questions about the sustainability of growth in the G6 systems sold and the potential for revenue recovery in Q2 due to backlog fulfillment.

Main topics on the call

• Revenue Performance — IRIDEX reported Q1 2026 revenue of $11.8 million, which was 'essentially flat year-over-year' and above prior guidance. The revenue decline was primarily due to lower retina system sales, partially offset by increased gl...
• Glaucoma Business Growth — The G6 probes segment showed strong growth with sales increasing to $3.6 million, a 14% year-over-year rise. Management noted that 'the loyalty physicians have to the G6 platform' is driving this growth, despite challeng...
• International Challenges — Management highlighted 'supply disruptions, regulatory delays, and geopolitical volatility' as significant challenges affecting international revenue, particularly in Asia and the Middle East. This environment has create...
• Cost Management Initiatives — Operating expenses decreased by 4% year-over-year to $5.1 million, attributed to lower general and administrative costs. The relocation of certain functions out of California is expected to yield annual savings of approx...

Read the full IRIDEX Corporation transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 29 IRIDEX Corporation earnings call transcripts on record, spanning March 12, 2020 to May 19, 2026. Based on this history, IRIDEX Corporation reports quarterly. The most recent call on file is dated May 19, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IRIX

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

29

First call

March 12, 2020

Most recent

May 19, 2026

Reporting cadence

quarterly